The University Hospital of Nîmes (CHU), a reference center in clinical research, has entrusted Medexprim with the construction of its IT environment dedicated to clinical research.
With a capacity of 2,064 beds, places and stations, the CHU groups together all medical and surgical specialties, and offers care ranging from local care to the management of rare and complex pathologies. Thanks to its cutting-edge technologies, the CHU is involved in a dynamic of excellence, progress and innovation.
Medexprim, a spin-off of the Toulouse University Hospital founded in 2015, is an accelerator of hospital clinical research and a tool for leveraging the data of hospitals. A leader in the extraction of imaging and clinical data, a technical and legal trusted third party, Medexprim provides hospitals with high-performance research environments, in compliance with ethics and the requirements of the CNIL (French National Commission on Information Technology and Liberties).
IT environments dedicated to clinical research are created to collect, structure, and deploy a large volume of data (relating to the care of the patient, socio-demographic, from previous studies, etc.), which is then reused mainly for study and research purposes. These environments facilitate multicenter research, feasibility studies for clinical trials and the development of artificial intelligence algorithms (predictive algorithms, screening assistance or decision-making assistance), while improving the management of hospital activity.
Nicolas Best, Director General of the CHU: “The CHU of Nîmes has always shown exceptional dynamism in terms of innovation and research. We are delighted with this collaboration which will accelerate the modernization and performance of the establishment in this field.”
Romain Cazavan, CEO of Medexprim: “We are honored that the CHU, one of the leading university hospitals in France, has entrusted us with the realization of its IT environments dedicated to clinical research. This is an extremely ambitious, progressive, and pragmatic project aimed at creating a universal solution dedicated to the specificities of the CHU and answering the clinicians’ concerns, when it comes to clinical research. This project must be the foundation of an ambitious policy of leveraging the CHU’s data.”
About the University Hospital of Nîmes
Nîmes University Hospital brings together a hospital community of 1,351 doctors (including students and interns) and 5,866 non-medical staff, spread over three sites:
– the Carémeau university hospital campus
– the Serre-Cavalier gerontology center
– the university hospital for rehabilitation, re-education, and addiction in Grau-du-Roi.
The fundamental missions of the establishment are care, teaching, research, and training. The CHU is also involved in prevention, health education, access to care and the fight against social exclusion. From local care to the treatment of rare and complex pathologies, the CHU is a reference center that brings together all medical and surgical specialties, to improve the quality of life of patients and their families. Thanks to its cutting-edge technologies, the CHU is involved in a dynamic of excellence, progress, and innovation. Strongly rooted in its territory, the CHU promotes human and civic values.
Jeremy Rosier – Director of Communication, Cultural Affairs & Patronage 04 66 68 30 91 / email@example.com
Chloë Diagne – Communication & Culture Officer, Deputy Manager 04 66 68 30 82 / firstname.lastname@example.org
Medexprim, founded in 2015 and based in Toulouse, Paris, London and Boston, is the European leader in imaging data and clinical data extraction, building bridges between hospitals and pharmaceutical companies to accelerate clinical research. An accelerator of hospital clinical research and a tool for leveraging the data of its partner hospitals in compliance with ethics and regulations, Medexprim helps pharmaceutical companies access specific datasets and design more successful, cost effective and faster clinical trials, through a network of leading hospitals and global data partners. With R-WiDE Strategy (From Real-World Imaging Data to Evidence), Medexprim wants to address clinical trial efficiency for biopharma by delivering synthetic patients thanks to its network of hospitals and its best-in-class international partners.
LinkedIn Romain Cazavan
LinkedIn Karine Seymour
LinkedIn Nicolas Dubost
Linkedin Fabrice Pillon
Press contact: Anne-Sophie Labeta